Schema-Root.org logo

 

  cross-referenced news and research resources about

 lymphomas

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Fri. April 13, 2018

-
The most common type of lymphoma is diffuse large B-cell lymphoma (DLBCL), accounting for about 1 in 3 lymphomas, and approximately half of these tumors are resistant to chemo-immunotherapy. Once the lymphoma originates in a lymphoid tissue, cell proliferation causes rupture of the tissue's ...
The background: The National Cancer Institute and other organizations have been studying for about 2 decades the effect of DNA mutations in a patient's tumors on their response to lymphoma treatments, according to study author Louis Staudt of the lymphoid malignancies branch of the NCI's Center ...

Hodgkin lymphoma (HL) is a B-cell driven hematological malignancy with 2 main subgroups -- classical and nodular lymphocyte predominant -- which are distinguished by cellular morphology and immunophenotype.1 Treatment for classical HL is determined after staging, which is performed using ...
"These findings are the culmination of two decades of research at NCI and elsewhere, advancing our understanding of the effect of DNA mutations and gene expression on lymphoma biology and outcome," said NCI Director Ned Sharpless, MD in a press release. "This refined molecular classification ...
The U.S. Food and Drug Administration (FDA) will review an application requesting duvelisib's full approval for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for relapsed/refractory follicular lymphoma (FL). The new ...
According to studies, breast implants have helped many women gain back their self-esteem and have a feeling of satisfaction. Breast implants bring positive effects on women who once had lost their confidence, but women should also be aware of what breast implants are being attributed to that can ...
... preclinical activity against EZH2-mutant non-Hodgkin lymphomas, INI1-negative rhabdoid tumors, and SMARCA4-negative rhabdoid tumors of the ovary. For this phase 1 study (ClinicalTrials.gov Identifier: NCT01897571), researchers enrolled patients with relapsed/refractory non-Hodgkin lymphoma ...
The FDA has granted a priority review to a new drug application (NDA) for duvelisib for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and an accelerated approval for the treatment of patients with ...
There is the use of maintenance rituximab following bendamustine/rituximab (BR) induction therapy. Though there are no clinical trials that are randomized to support this approach, there were some retrospective studies and analyses of prior follicular lymphoma cohorts that suggest a similar PFS benefit.
ORLANDO, Fla. (WOFL-Fox35) -- Keishla Betancourt's life in Puerto Rico was already in danger when Hurricane Maria struck. The 23 year old is battling Hodgkin's lymphoma, and doctors said she had only two weeks to live. “A clot that was going up very fast and was going to hit my heart in two weeks.
Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869-881. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014 ...
He, from there, was referred to a surgeon who did a biopsy of one of the lymph nodes, which revealed grade 2 follicular lymphoma, and was referred from there to a hematologist who saw the cytopenias and did a bone marrow biopsy, which also found involvement of follicular lymphoma in the bone marrow ...
FDA approvals in chronic myeloid leukemia and Hodgkin lymphoma, a priority review designation in colorectal cancer, a breakthrough therapy designation in urothelial carcinoma, a rolling new drug application completed in TRK-fusion cancers, and promising phase III findings in a lung cancer trial.
Certain quantitative PET parameters can help clinicians predict how well patients with Hodgkin's lymphoma will react to their treatment, according to preliminary results from a study conducted in the Ukraine and presented at ECR 2018 in Vienna. In a comparison of several variables, the researchers found ...
And in that clinical trial, a group of physicians around the country treated people with rituximab- and alkylator-refractory follicular lymphoma. So, in other words, we treated a group of patients who were probably more resistant to therapy than this patient, where they had to have relapsed within 6 months of ...
Patients included in the study had asymptomatic follicular lymphoma and were deciding between active treatment utilizing rituximab or watchful waiting. If a patient experienced a relapse after active treatment, then he or she would be given another chemotherapy regimen with or without rituximab or an ...

TTI-621, an investigational molecule developed by Trillium that turns macrophages against tumor cells, was granted orphan drug status by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. The designation aims to encourage therapies for rare and serious diseases by ...
The US Food and Drug Administration has approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. “Today's approval represents an improvement in the initial treatment regimens of ...
Voxtalisib, an investigational agent that targets both mammalian target of rapamycin (mTOR) and multiple isoforms of phosphoinositide-3 kinase (PI3K), showed “promising” efficacy with acceptable safety in patients with relapsed or refractory follicular lymphoma, results of a phase 2 trial indicate. Among 46 ...
The FDA has approved brentuximab vedotin (Adcetris, Seattle Genetics, Inc.) in combination with chemotherapy in adult patients with previously untreated stage III or IV classical Hodgkin's lymphoma. The approval is based on the successful outcome of the phase 3 ECHELON-1 clinical trial that compared ...
The disease is not breast cancer but is a malignancy of the immune system called breast-implant-associated anaplastic large-cell lymphoma. When detected early, it can usually be cured by surgery alone, by removing the implant and the capsule of scar tissue that forms around it. But some women have ...
One of the driving forces behind non-Hodgkin lymphomas is the over-activation of a receptor on the surface of B cells. This receptor normally stimulates the growth of B-cells only when it is needed, but in non-Hodgkin lymphoma, the growth signal is constantly on, making B-cells grow uncontrollably.
The disease is not breast cancer, but is a malignancy of the immune system called breast implant-associated anaplastic large-cell lymphoma. When detected early, it can usually be cured by surgery alone, by removing the implant and the capsule of scar tissue that forms around it. But some women have ...
The FDA has approved brentuximab vedotin (Adcetris) for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma, according to a statement from Seattle Genetics, the manufacturer of the CD30-targeted antibody-drug conjugate.
Actor Trefor Selway has died at the age of 86 after suffering with lymphoma. Mr Selway, who was born in Pandy Tudur in Conwy county, was known for his work in English and Welsh, including the films A Mind To Kill and Wild Justice. He appeared in the Welsh language series Y Palmant Aur and Hafod ...
Imbruvica (ibrutinib) is only moderately effective against tumors in patients with relapsed follicular lymphoma, and certain clinical and genetic factors may have an impact on patient response, according to results from a Phase 2 clinical trial. Specifically, researchers found that patients who did not previously ...
The phase I trial, which was conducted at 7 clinics in the United States, included ninety adult patients with CLL (27%; n = 24), B-cell non-Hodgkin lymphoma (54%; n = 49), Hodgkin lymphoma (12%; n = 11), or other hematological malignancies (7%; n = 6). Patients were enrolled between January 2013 and ...
“You're sure it's Hodgkin lymphoma?” he asked. Pleasant was sure, and before long he was on a conference call with a friend of his boss at Seattle Genetics, which had been developing Adcetris (brentuximab vedotin) for the treatment of Hodgkin lymphoma. Adcetris targets CD30, which is found on the ...
Worldwide clinical trials may greatly improve and enhance management of Hodgkin lymphoma, according to a recent article published in Clinical Medicine Insights: Oncology. Thomas J. FitzGerald, MD, and Maryann Bishop-Jodoin, MEd, analyzed the differences between Hodgkin lymphoma treatment in ...
“In lymphomas in general, and aggressive lymphomas in particular, the data are much more limited. We are a little late to the game,” John ... Outcomes for patients with relapsed/refractory B-cell lymphoma have generally improved over time, but still remain poor. Outcomes improve slightly if patients are able ...
“Survivors of Hodgkin lymphoma have a high risk of developing a subsequent breast cancer, particularly after chest irradiation,” researchers from the Radiation Epidemiology Branch in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Bethesda, Maryland, wrote.
Classical Hodgkin lymphoma (cHL) has a cure rate of about 75% with standard chemotherapy. Its nearly universal genetic alterations, furthermore, likely contribute to its unique sensitivity to PD-1 blockade. Most non-Hodgkin lymphomas (NHL) do not, however, have the same genetic alterations as cHL, ...
254 achieved complete remission after the first course of treatment (127 with DLBCL, 91 with Burkitt's lymphoma, 29 with plasmablastic lymphoma and seven with other non-classifiable B-cell lymphomas). This group represented just under two-thirds (63%) of those treated. Complete remission from ...
The phase I trial, which was conducted at 7 clinics in the United States, included ninety adult patients with CLL (27%; n = 24), B-cell non-Hodgkin lymphoma (54%; n = 49), Hodgkin lymphoma (12%; n = 11), or other hematological malignancies (7%; n = 6). Patients were enrolled between January 2013 and ...
OTTAWA -- Liberal MP Salma Zahid says she's taking a medical leave to be treated for non-Hodgkin's lymphoma. Zahid, who represents a Toronto-area riding, says she received the diagnosis in the last week. It followed weeks of intermittent pain that began after an overseas visit during the holidays.
Scholarship helps Sarah reach her dreams after beating lymphoma ... In July 2016, halfway through Year 12, the Dubbo student was diagnosed with Non-Hodgkin Lymphoma. “I had surgery to remove the tumour, so it was an open-heart type surgery and following that I had four round of chemotherapy,” ...
I had already begun the tattoo addiction on my right arm before being diagnosed with lymphoma. Once diagnosed and well into treatment, I knew that getting a tattoo once I completed treatment was a must. Although I didn't yet know exactly what I wanted. Following my chemo treatment, I was on blood ...
Thymic lymphoma in a ferret. Lymphoma is common in ferrets, according to Bruce H. Williams, DVM, DACVP, senior pathologist at the Joint Pathology Center in Silver Spring, Maryland. “Lymphoma is the third most common tumor overall in ferrets and by far the most common malignancy,” he said.
Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses BTK inhibitors in mantle cell lymphoma (MCL). Acalabrutinib (Calquence) joined ibrutinib (Imbruvica) in late 2017 as the second FDA-approved BTK inhibitor for the treatment of patients with MCL.
And we will also be thinking about evaluating axi-cel in the frontline setting in patients, especially high-risk, who have aggressive non-Hodgkin's lymphoma such as high-grade B-cell lymphomas. In addition, we are also thinking about adding axi-cel in patients with mantle cell lymphoma as well as indolent ...
Panelists: Alexey V. Danilov, MD, PhD, Oregon Health & Science University; Andre Goy, MD, Hackensack University Medical Center; John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medical Center; John M. Pagel, MD, PhD, DSc, Swedish Medical Center Seattle and Issaquah; Stephen J.
A new drug application has been submitted to the FDA for duvelisib for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, as well as an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.
Ian W. Flinn, MD, PhD: Peter, CAR T cells are now approved for the treatment of refractory diffuse large cell lymphoma with some really impressive activity and also some concerning toxicity. There are certainly trials that are ongoing to accrue patients with follicular lymphoma. Are we going to be treating ...
Furthermore, the gene panel that the researchers developed identified at least one mutation in 91 percent of tumors from 219 lymphoma patients. The assay was also able to determine subtype-specific mutation patterns and frequencies that were consistent with those previously known in published studies.
Sattva S. Neelapu, MD: Axicabtagene ciloleucel, also called axi-cel, was FDA approved earlier this year on October 18th for patients with adult large B-cell lymphoma who have failed at least 2 or more lines of therapy. So, this therapy can be used in at least 4 different subtypes of lymphoma, including ...
Antitumor effect of triptolide in T-cell lymphoblastic lymphoma by inhibiting cell viability, invasion, and epithelial–mesenchymal transition via regulating the PI3K/AKT/mTOR pathway. Abstract ... Introduction: T-cell lymphoblastic lymphoma (T-LBL) is a widely disseminated disease worldwide. Triptolide (TPL) ...
The Food and Drug Adminsitration (FDA) has granted accelerated approval for Calquence (acalabrutinib) for adults who have been previously treated for mantle cell lymphoma. This type of B-cell non-Hodgkin lymphoma tends to grow more quickly than other types of lymphomas and to be difficult to treat.
The researchers evaluated both Agilent's SureSelect hybrid capture method and Illumina's TruSeq amplicon technology on FFPE lymphoma samples. ... Although there are some commercially available panels for leukemias and lymphomas, like Foundation Medicine's FoundationOne Heme , Steidl said ...
Verastem recently announced it has submitted a new drug application (NDA) seeking full approval for duvelisib, an investigational phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma inhibitor for relapsed or refractory (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), ...


 

news and opinion


 


 


 


 


schema-root.org

   human
    diseases
     cancer
       lymphoma
         hodgkin's
         non‑hodgkin's

cancers:
       brain
       breast
       cervix
       colon
       lung
       lymphoma
       oral
       radiogenic
       skin